Top-Three CRO Signs Master Services Agreement with NewCardio

Article

Company News Release

Santa Clara, CA-August 27, 2009

NewCardio, Inc., a cardiac diagnostic and services company, announced that a top-three contract research organization has signed a Master Services Agreement (MSA) to use the company's QTinno software suite as its technology in fully automated Thorough QT (TQT) and Phase 1 studies delivered by its centralized ECG core lab.

NewCardio expects to collaborate on the first fully automated study, tentatively scheduled to begin during the third quarter of 2009.

NewCardio’s innovative 3D ECG platform technology is intended to improve the accuracy and increase the diagnostic value of the standard 12-lead electrocardiogram (ECG). QTinno is a software suite that provides an automated analysis of QT intervals and other ECG-based cardiac safety for the pharmaceutical industry and drug regulators.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Related Content
© 2024 MJH Life Sciences

All rights reserved.